MSLN and neoplasm: investigated bispecific antibodies with mesothelin targeting and CD16 engagement domains, and demonstrated that this construct mediated the recruitment and penetration of natural killer (NK) cells into tumor spheroids and provoked robust dose-dependent cell-mediated cytotoxicity of mesothelin-expressing TNBC cell lines (212).